GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Clene Inc.
Clene is a biotech company developing gold nanocrystal-based drugs for the treatment of neurodegenerative diseases. Its stock price is highly volatile, reflecting the hopes and setbacks of its clinical trials.
Share prices of companies in the market segment - Neuro
Clene Inc. is a biopharmaceutical company that has developed a technology for creating pure gold nanocrystals, which are used in drugs for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis. We have classified it in the "Neuro" segment. The chart below shows the overall dynamics of this innovative sector.
Broad Market Index - GURU.Markets
Clene is a biotech company that has developed a technology for creating pure metal nanocrystals to treat neurodegenerative diseases. Its unique approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Clene compares to it.
Change in the price of a company, segment, and market as a whole per day
CLNN - Daily change in the company's share price Clene Inc.
For Clene Inc., which develops drugs to treat neurodegenerative diseases, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment.
Daily change in the price of a set of shares in a market segment - Neuro
Clene Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with CLNN, which focuses on neurodegenerative diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Clene has developed a technology for producing gold nanocrystals for the treatment of neurodegenerative diseases. This innovative biotech company's shares are reacting to research data. Its story exemplifies the medical technology sector's contribution to overall market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Clene Inc.
Clene Inc.'s year-over-year performance is a story about the development of its unique nanocrystal therapy. Its 12-month market cap is entirely dependent on clinical trial data for its lead drug for neurodegenerative diseases such as ALS and multiple sclerosis. Success could lead to a breakthrough in the treatment of these complex conditions.
Annual dynamics of market capitalization of the market segment - Neuro
Clene Inc. is a biopharmaceutical company developing nanocatalytic therapies for the treatment of neurodegenerative diseases. Its stock price is extremely volatile, reflecting investor confidence in its breakthrough scientific potential rather than its current financial performance, which is typical for this speculative sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Clene is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Clene Inc.
Clene is a biotech company developing nanocrystal drugs for the treatment of neurodegenerative diseases. Its monthly growth is entirely dependent on the results of its clinical trials. Data from its ALS and multiple sclerosis treatment programs are the main drivers.
Monthly dynamics of market capitalization of the market segment - Neuro
Developing drugs for neurodegenerative diseases is one of the most complex and risky areas in biotechnology. The sector's dynamics, as seen on the chart, reflect its high volatility. In this high-stakes environment, companies like Clene are pursuing breakthrough treatments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Clene, a biopharmaceutical company developing drugs to treat neurodegenerative diseases, lives by the laws of science. Its shares are driven by news of trials, and their performance is completely disconnected from overall economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Clene Inc.
Short-term price fluctuations for Clene, a biopharmaceutical company developing gold nanocrystal-based drugs, are extremely high. News about the progress of clinical trials for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases is causing sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Neuro
Clene shares, like the entire neuroscience biotech sector, are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major study can impact the entire industry. The chart shows how the company fares against this volatile backdrop.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Clene shares, like the entire neuroscience biotech sector, are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major study can impact the entire industry. The chart shows how the company fares against this volatile backdrop.
Market capitalization of the company, segment and market as a whole
CLNN - Market capitalization of the company Clene Inc.
Clene's market capitalization is the financial valuation of a biotech company with a unique platform for creating gold nanocrystals for the treatment of neurodegenerative diseases. The chart reflects investor hopes for its innovative approach. Its speculative dynamics tell the story of how the market weighs scientific potential against the risks of clinical trials.
CLNN - Share of the company's market capitalization Clene Inc. within the market segment - Neuro
Clene develops nanocrystal therapeutics for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis. Its market share reflects the potential of its unique therapeutic platform. The chart below is an indicator of the market's confidence in its innovative scientific approach.
Market capitalization of the market segment - Neuro
Clene is developing nanocrystal-based therapies for the treatment of neurodegenerative diseases. The chart below shows the total market capitalization of the entire sector, reflecting hopes for breakthroughs in the treatment of diseases such as amyotrophic lateral sclerosis (ALS). Clene's scientific approach is a bold bet on nanotechnology.
Market capitalization of all companies included in a broad market index - GURU.Markets
Neurological diseases like amyotrophic lateral sclerosis (ALS) are a challenge for biotechnology, as seen in the chart. Clene Inc. is developing a nanocrystal drug to improve energy metabolism in brain cells. Its capitalization represents a risky bet on this new approach to treating neurodegeneration.
Book value capitalization of the company, segment and market as a whole
CLNN - Book value capitalization of the company Clene Inc.
Clene's chart represents the raw material base for creating nanocrystalline drugs. Its book value reflects the value of its unique manufacturing process and equipment, which allows for the creation of pure metal suspensions for the treatment of neurodegenerative diseases.
CLNN - Share of the company's book capitalization Clene Inc. within the market segment - Neuro
Clene, a biopharmaceutical company, has developed a unique nanocrystal production technology. Its stake in the sector's assets lies in its specialized manufacturing facilities. This physical base allows it to create drugs for the treatment of neurodegenerative and other diseases.
Market segment balance sheet capitalization - Neuro
Clene Inc. has developed a unique technology for producing nanocatalytic drugs. Its business is becoming increasingly capital-intensive, requiring the construction of its own GMP-compliant manufacturing facilities. Compared to the biotech sector, this demonstrates its strategy of achieving complete control over its innovative manufacturing platform.
Book value of all companies included in the broad market index - GURU.Markets
Clene's assets are not traditional drugs, but a unique technology for producing pure gold nanocrystals designed to treat neurodegenerative diseases. The company's balance sheet reflects the value of this innovative production process. The chart shows the capital invested in this "golden" therapy.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Clene Inc.
Clene develops nanocrystal drugs for the treatment of neurodegenerative diseases. Its market value is almost entirely a bet on its unique technological platform. The chart shows how investors assess the chances of success in treating complex diseases like amyotrophic lateral sclerosis.
Market to book capitalization ratio in a market segment - Neuro
Clene develops nanocrystal-based drugs for the treatment of neurodegenerative and other diseases. Its value lies in its unique scientific platform. This chart shows how the market valuation based on the potential of this technology is many times greater than the book value of the manufacturing equipment.
Market to book capitalization ratio for the market as a whole
Clene is a biopharmaceutical company developing nanocrystalline drugs for the treatment of neurological diseases. Its market cap is based on the potential of this unique technological platform. This chart shows how the market values the innovative scientific platform, rather than the company's tangible assets, in anticipation of a breakthrough.
Debts of the company, segment and market as a whole
CLNN - Company debts Clene Inc.
Clene Inc. is developing nanocrystal-based therapies for the treatment of neurodegenerative diseases. Translating such a unique technology from the laboratory to the clinic requires enormous resources. Debt financing is part of the company's strategy to secure capital for costly clinical trials.
Market segment debts - Neuro
Clene Inc. is a biopharmaceutical company developing nanotherapeutics for neurological diseases. Funding during the clinical trial stage is critical. This chart shows whether the company is following a standard equity capital model to fund its expensive and time-consuming research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Clene Inc.
Clene, a biopharmaceutical company focused on neurodegenerative diseases, funds its expensive research. This chart shows its level of reliance on debt. It's a classic example of high-risk investment, where debt can either pay off many times over if the drug is successful or lead to bankruptcy if it fails.
Market segment debt to market segment book capitalization - Neuro
Clene Inc. has developed a technology for creating pure gold nanocrystals used in drugs for the treatment of neurodegenerative diseases. This chart compares the debt raised for this unique research with the total market capitalization of the entire neuroscience sector. It reflects the financial risks associated with developing a revolutionary therapy.
Debt to book value of all companies in the market
Clene Inc. is a biopharmaceutical company developing nanocrystalline drugs for the treatment of neurological diseases. Funding clinical trials is its primary goal. The chart shows how the company manages its debt along the way. Comparisons with other biotech companies allow for an assessment of risks and potential before a product reaches market.
P/E of the company, segment and market as a whole
P/E - Clene Inc.
For Clene, a biotech company developing nanocrystal drugs to treat neurodegenerative diseases, this chart represents the valuation of its unique technology. Investors' estimates of potential profit are very high due to the huge unmet need for treatment. The stock's performance is a direct response to clinical trial data.
P/E of the market segment - Neuro
This chart reflects the average valuation for the speculative biotech sector—a benchmark for Clene. The entire sector is valued based on expectations for future drugs. For investors, this benchmark indicates the overall level of optimism. Against this backdrop, one can judge expectations for Clene's unique nanocrystal technology.
P/E of the market as a whole
Clene is developing a therapy based on pure gold nanocrystals for the treatment of neurodegenerative diseases. This is a unique and innovative scientific approach. The company's value depends on the success of its clinical trials. This chart shows the overall interest in biotechnology. It helps us understand whether the market believes in the potential of this unusual technology and how its valuation responds to scientific data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Clene Inc.
Clene develops nanocrystal drugs for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). For a clinical-stage company, this graph reflects its hopes. It shows the future value analysts attribute to its technology if clinical trials are successful.
%20P%2FE%20Clene%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Clene-Inc.&v=1772671230095 "Chart of the company's future (projected) P/E Clene Inc.")
Future (projected) P/E of the market segment - Neuro
Clene Inc. is a biopharmaceutical company developing therapeutics based on pure gold nanocrystals for the treatment of neurodegenerative diseases. This chart shows how its profitability expectations compare to the biotech sector. It reflects investor confidence in its unique technology platform and its potential to treat ALS and multiple sclerosis.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772671230110 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Clene develops nanocrystal drugs for the treatment of neurodegenerative diseases. This chart shows the company's overall risk appetite. Clene's success depends on the results of clinical trials. A positive market environment helps with funding, but cannot replace scientific data, which is the primary driver of the company's value.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772671230152 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Clene Inc.
Clene develops nanocrystal drugs for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis. This chart shows the biotech company's financial progress through clinical trials. Current results reflect its investment in research in hopes of creating breakthrough therapies.
Profit of companies in the market segment - Neuro
Clene develops therapeutics based on pure gold nanocrystals that aim to improve neurological function in diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis. This graph illustrates the total revenue in the neuroscience sector, demonstrating the commercial potential of breakthrough approaches to treating neurodegenerative diseases.
Overall market profit
Clene Inc. develops nanocrystalline drugs for the treatment of neurodegenerative diseases. The company's success depends entirely on the results of clinical trials. The need for treatments for Parkinson's disease or multiple sclerosis does not change with the economic climate. However, the investment climate for biotech depends on overall market sentiment.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Clene Inc.
Clene is developing a therapy based on pure gold nanocrystals for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis. This is a revolutionary scientific approach. The profit projection is a long-term model based on analysts' confidence in the clinical success of this unique technology.
%20profit%20of%20the%20company%20Clene%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Clene-Inc.&v=1772671230372 "Graph of future (projected) profit of the company Clene Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Clene Inc. is developing a pure gold nanocrystal-based therapy for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart shows forecasts for the biotech sector. Clene's future profits depend on the success of its unique technology in clinical trials, which could lead to a breakthrough in the treatment of serious diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772671230439 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Clene Inc. is developing nanocrystal drugs for the treatment of neurodegenerative diseases. Funding for such innovative research is directly dependent on investor risk appetite. This chart, reflecting overall profit expectations, serves as an indicator of the stock market and investor willingness to invest in long-term, capital-intensive biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772671230450 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Clene Inc.
Clene is a biopharmaceutical company developing nanocrystal drugs for the treatment of neurodegenerative diseases. This chart shows that the company's valuation is based on future potential. It reflects investors' hopes that its unique technology will offer new solutions for diseases such as ALS and multiple sclerosis.
P/S market segment - Neuro
Clene Inc. is a biopharmaceutical company that has developed technology for creating pure gold nanocrystals used to treat neurodegenerative diseases such as amyotrophic lateral sclerosis. This chart shows the average biotech valuation, helping to understand how highly the market values this unique and innovative therapeutic platform.
P/S of the market as a whole
Clene is developing a pure gold nanocrystal-based therapy for the treatment of neurodegenerative diseases. This is a unique and innovative approach to medicine. This graph of average market revenue estimates clearly demonstrates that Clene's valuation is based not on current sales, but on investor expectations for a breakthrough in the treatment of serious diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Clene Inc.
Clene is developing pure gold nanocrystal-based drugs for the treatment of neurodegenerative diseases. This chart reflects investors' confidence in this unique technology. The valuation is based on the potential future revenue from its drugs, which, if successful in clinical trials, could offer a new treatment approach.
%20P%2FS%20Clene%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Clene-Inc.&v=1772671230549 "The graph of the company's future (projected) P/S Clene Inc.")
Future (projected) P/S of the market segment - Neuro
Clene is developing pure gold nanocrystal-based therapies for the treatment of neurodegenerative diseases. This chart compares the company's future revenue expectations with its industry. It reflects investor confidence in Clene's unique scientific approach and the potential of its drugs to address complex medical challenges.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772671230588 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Clene is a biopharmaceutical company developing nanocrystal drugs for the treatment of neurodegenerative diseases. This chart reflects confidence in future growth, as Clene tackles one of the most challenging problems in medicine. The success of its therapy could bring hope to millions of patients and open a huge new market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772671230602 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Clene Inc.
Clene Inc. is a biopharmaceutical company developing nanocrystal therapeutics for the treatment of neurodegenerative diseases. Because its products are in the research stage, revenue shown in this chart, if any, likely comes from grants or collaborative agreements rather than commercial sales.
Sales of companies in the market segment - Neuro
Clene Inc. is a biopharmaceutical company developing nanocrystal drugs for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart reflects the enormous hope and investment in the neuroscience sector, where the need for effective treatments remains extremely high.
Overall market sales
Clene Inc. develops nanocrystal drugs for the treatment of neurodegenerative diseases. The company's operations require significant investment in R&D. Periods of revenue growth, reflected in this chart, create a favorable investment climate. Investors are becoming more inclined to fund the breakthrough yet long-term scientific projects Clene is pursuing.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Clene Inc.
Clene Inc. is a biopharmaceutical company developing gold nanocrystal-based therapeutics for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart reflects analyst expectations for clinical trial results for this innovative technology.
%20sales%20of%20the%20company%20Clene%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Clene-Inc.&v=1772671230694 "Schedule of future (projected) sales of the company Clene Inc.")
Future (projected) sales of companies in the market segment - Neuro
Clene develops nanocrystal drugs for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis and multiple sclerosis. This chart shows forecasts for the neuroscience sector. It provides context for assessing the potential of Clene's breakthrough technology in one of the most complex and innovative areas of medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772671230722 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Clene, a biopharmaceutical company developing nanotherapies for neurodegenerative diseases, sees this chart as an indicator of the market's readiness for innovation. The strong economic forecasts reflected here are driving capital flows into biotech and creating an environment in which the healthcare system is more open to new approaches to treating complex diseases.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772671230738 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Clene Inc.
Clene is a clinical-stage biopharmaceutical company developing nanotherapeutics for neurological diseases. This chart reflects its current state: it is in the phase of significant investment in research and clinical trials. It shows how capital is being used to advance innovative development rather than to generate current profits.
Market segment marginality - Neuro
Clene develops nanocrystal drugs for the treatment of neurodegenerative diseases. In this complex field of pharmaceuticals, efficiency is the ability to advance innovative research without burning through capital too quickly. The data allows us to assess how Clene's operating model compares to other biotech companies working on breakthrough drugs.
Market marginality as a whole
Clene is developing a therapy based on pure gold nanocrystals for the treatment of neurodegenerative diseases. This chart shows the profitability of traditional pharmaceuticals, while Clene offers a completely new approach. Their financial history is one of investing in a breakthrough technology with potential widespread applications.
Employees in the company, segment and market as a whole
Number of employees in the company Clene Inc.
Clene develops unique nanotherapeutics for the treatment of neurodegenerative diseases. Its team, shown in this graph, is a cutting-edge research team working on breakthrough technology. The size of its staff is an indicator of the intensity of its research and clinical trials of innovative drugs.
Share of the company's employees Clene Inc. within the market segment - Neuro
Clene is developing a therapeutic approach based on pure gold nanocrystals for the treatment of neurodegenerative diseases. This unique technology requires a team of top chemists and biologists. The graph shows the percentage of all scientists in this cutting-edge field that Clene attracts, a measure of its scientific leadership and potential to create breakthrough treatments.
Number of employees in the market segment - Neuro
Clene is a biopharmaceutical company developing nanocrystal drugs for the treatment of neurodegenerative diseases. Its main asset is its scientific team. This chart shows its investment in R&D. The growth in headcount reflects progress in clinical trials and efforts to prove the efficacy of its unique technology platform.
Number of employees in the market as a whole
Clene Inc. develops nanotherapeutic drugs for the treatment of neurodegenerative diseases. For such an innovative biopharmaceutical company, hiring trends are determined not by the overall labor market situation, but by research progress. The success of Phase III trials is more important than this graph.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Clene Inc. (CLNN)
Clene develops nanocrystalline drugs. It's a science-intensive R&D company. This chart shows that its market capitalization is the market's valuation of its unique technology. A very high per-employee ratio is typical for biotech, where intellectual property is the primary asset.
%20of%20the%20company%20Clene%20Inc.%20(CLNN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Clene-Inc.-CLNN&v=1772671231148 "Chart of market capitalization per employee (in thousands of dollars) of the company Clene Inc. (CLNN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Clene Inc. develops nanocatalytic drugs for the treatment of neurodegenerative diseases. In this complex field of biotechnology, market valuation reflects the hopes for a scientific breakthrough. This metric demonstrates the value investors attribute to the intellectual potential of the team working on the development of next-generation drugs.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772671231180 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Clene is developing nanocrystal-based therapies for the treatment of neurodegenerative diseases. It is an innovative biotech company. The chart demonstrates the high market valuation of this unique technological platform, where the potential of a single drug developed by a small scientific team can be measured in billions of dollars.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772671231239 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Clene Inc. (CLNN)
Clene is a biopharmaceutical company developing nanocatalysts for the treatment of neurodegenerative diseases (ALS, multiple sclerosis). It's an R&D company at the intersection of chemistry and medicine. This chart shows the R&D capital burn per scientist. This represents an investment in a unique technological platform.
%20Chart%20Clene%20Inc.%20(CLNN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Clene-Inc.-CLNN&v=1772671231253 "Company Profit Per Employee (in thousands of dollars) Chart Clene Inc. (CLNN)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Clene (CLNN) is a biopharmaceutical company developing nanocrystalline drugs for the treatment of neurodegenerative diseases. Their key asset is their scientific platform. This chart shows how effectively their team of scientists and management utilize capital to advance their unique drugs through clinical trials, creating value per employee in an R&D-intensive business.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772671231316 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Clene Inc. is a biotech company developing nanocrystal-based drugs (for example, for the treatment of multiple sclerosis). It is a science-intensive business in clinical trials. This chart shows a classic biotech picture: negative profit per employee, as the company invests in scientists and research that is not yet generating revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772671231350 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Clene Inc. (CLNN)
Clene is developing nanocrystal drugs for the treatment of neurodegenerative diseases. For a research-stage biotech company, this graph is a promising future. Zero or low revenue per employee is the norm, and any income is likely the result of partnerships rather than sales.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Clene-Inc.-CLNN&v=1772671231404 "Sales chart per company employee Clene Inc. (CLNN)")
Sales per employee in the market segment - Neuro
Clene Inc. is a biopharmaceutical company developing nanocrystal drugs for the treatment of neurodegenerative diseases (ALS, multiple sclerosis). This chart shows the average revenue per employee in the sector. For Clene, with its unique R&D platform, this is a benchmark. It demonstrates the level of productivity required in the industry to successfully commercialize such complex drugs.
Sales per employee for the market as a whole
Clene Inc. (CLNN) is a biopharmaceutical company developing nanocrystal drugs for the treatment of neurodegenerative diseases (ALS, multiple sclerosis). This is a science-intensive R&D company. This chart shows the current (minimum) partnership revenue per scientist. This trend will only change if their unique platform is commercialized.
Short shares by company, segment and market as a whole
Shares shorted by company Clene Inc. (CLNN)
Clene is a biopharmaceutical company developing nanocatalysts for the treatment of neurodegenerative diseases such as ALS and multiple sclerosis. This is a very complex area of medicine. The chart shows the number of investors who are skeptical of this new technology and are betting that it will not prove effective in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Clene-Inc.-CLNN&v=1772671231573 "Short Shares Chart for the Company Clene Inc. (CLNN)")
Shares shorted by market segment - Neuro
Clene is developing a unique nanocrystal-based therapy (CNM-Au8) for the treatment of neurodegenerative diseases such as ALS. This chart illustrates the skepticism surrounding this entire niche. Its growth suggests that investors are massively betting against this new technology, expecting it to fail in clinical trials, like many others in this field.
Shares shorted by the overall market
Clene develops nanocrystal drugs for the treatment of neurodegenerative diseases (ALS, multiple sclerosis). It's a biotech company with a very long R&D cycle. This chart illustrates the general market fear. When investors panic, they're unwilling to wait 5-10 years for clinical trial results, preferring to cash out immediately.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Clene Inc. (CLNN)
This oscillator for Clene highlights the extreme speculative nature of neuroscience. The company is developing nanocatalytic therapy for severe diseases such as ALS and multiple sclerosis. This is a revolutionary approach. Any encouraging data, even from small studies, triggers an explosive "overheating" (above 70). A failure in a key study or doubts about the mechanism of action lead to a collapse (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Clene-Inc.-CLNN&v=1772671231649 "RSI 14 indicator chart for the company's stock Clene Inc. (CLNN)")
RSI 14 Market Segment - Neuro
Clene (CLNN) is "nano-medicine." Their specialty is gold nanocrystals (CNM-Au8), which (they claim) repair cellular energy to treat neurodegenerative diseases (ALS, Parkinson's). The "Neuro" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the entire segment. It's vital to understand: is CLNN's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Clene (CLNN) is a biotech R&D company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CLNN (Clene Inc.)
Clene (CLNN) is a biotech company developing a gold nanocrystal (CNM-Au8)-based therapy for the treatment of neurodegenerative diseases (ALS, multiple sclerosis). This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of this unique platform and its chances of success in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CLNN-Clene-Inc.&v=1772671231680 "A chart showing analyst consensus forecasts for the expected stock price. CLNN (Clene Inc.)")
The difference between the consensus estimate and the actual stock price CLNN (Clene Inc.)
Clene (CLNN) is a biotech company whose platform (CNM-Au8) creates gold nanocrystals to treat neurodegenerative diseases (ALS, multiple sclerosis). This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their unique gold therapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CLNN-Clene-Inc.&v=1772671231766 "A chart showing the difference between the consensus forecast and the actual stock price. CLNN (Clene Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Clene is a biotech company trying to "recharge" the brain. It is developing gold nanocrystals (CNM-Au8) for the treatment of neurodegenerative diseases (ALS, multiple sclerosis). This chart reflects analyst expectations across the neuroscience sector, demonstrating whether experts believe a breakthrough in the treatment of these complex diseases is possible.
Analysts' consensus forecast for the overall market share price
Clene is a clinical-stage biotech company specializing in neurological disorders. It's an R&D company that's burning cash. This chart, reflecting the market's overall risk appetite, is vital. When optimism is high, investors fund speculative science. When pessimism ("risk-off") takes over, funding for biotechs like CLNN dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Clene Inc.
Clene is a biotech company with unique nanoscience. Their platform produces pure metal nanocrystals (gold, silver), which, according to their theory, can restore neurons to treat diseases (ALS, Parkinson's). This chart is a clear indicator of faith in their R&D. Its dynamics reflect the market's speculative assessment of their unconventional scientific platform and clinical trial data.
AKIMA Market Segment Index - Neuro
Clene Inc. (CLNN) is a biopharmaceutical company developing nanocrystal therapeutics for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis. The chart shows the segment average, allowing investors to assess how the risks and potential of this unique technology compare to the neuroscience sector average.
The AKIM Index for the overall market
Clene is a biopharmaceutical company developing nanocatalytic drugs for the treatment of neurodegenerative diseases (ALS, multiple sclerosis). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative scientific story compares to overall economic trends and clinical data.
